Alectinib: Uses, Dosage, Side Effects & ALK-Positive Lung Cancer
Alectinib: Uses, Dosage, Side Effects & ALK-Positive Lung Cancer
Alectinib is an oral targeted anticancer medicine used for eligible patients with ALK-positive non-small cell lung cancer (NSCLC). It belongs to a class of medicines called ALK tyrosine kinase inhibitors (ALK TKIs), which are designed to block abnormal ALK signalling involved in cancer-cell growth and survival.
Alectinib is a prescription medicine and should be used under the supervision of an oncologist or other qualified healthcare professional. Treatment is generally considered after appropriate molecular testing confirms that the tumour has an ALK alteration.
Alectinib 150 mg capsules contain 150 mg of alectinib per capsule. The number of capsules required for an individual dose depends on the total dose prescribed by the treating physician.
What Is Alectinib Used For?
Alectinib is used for specific patients with ALK-positive non-small cell lung cancer. Depending on the approved indication and clinical setting, it may be used in adults with advanced disease and in certain patients following complete surgical removal of an ALK-positive tumour.
- Advanced ALK-positive NSCLC: Alectinib can be used as targeted treatment for eligible adults with advanced ALK-positive non-small cell lung cancer.
- Previously treated ALK-positive NSCLC: It may be prescribed for eligible patients who have previously received another ALK-targeted treatment such as crizotinib.
- Adjuvant treatment: In appropriate patients, alectinib may be used after complete surgical removal of ALK-positive NSCLC when there is a significant risk of recurrence.
How Does Alectinib Work?
Alectinib works by targeting anaplastic lymphoma kinase (ALK), a protein involved in cellular signalling. Some lung cancers contain genetic changes that cause abnormal ALK activity. This abnormal signalling can encourage cancer cells to multiply, survive and continue growing.
Alectinib inhibits ALK tyrosine kinase activity and interferes with signalling pathways that support ALK-dependent cancer-cell proliferation. By suppressing this cancer-driving pathway, the medicine can help control the growth and progression of susceptible ALK-positive tumour cells.
The basic therapeutic pathway can be summarized as:
ALK alteration → abnormal ALK signalling → cancer-cell growth → tumour progression
Alectinib acts by inhibiting the ALK signalling step:
Alectinib → ALK inhibition → reduced abnormal signalling → reduced proliferation of susceptible cancer cells
Alectinib is therefore considered a molecularly targeted therapy rather than conventional cytotoxic chemotherapy. Treatment response varies between patients, and alectinib should not be considered a guaranteed cure for lung cancer.
Key Indications
ALK-Positive Advanced NSCLC
Alectinib may be prescribed for adults with advanced non-small cell lung cancer whose tumour has been confirmed as ALK-positive through appropriate molecular testing.
ALK-Positive NSCLC After Previous Treatment
Alectinib may provide a targeted treatment option for eligible patients with ALK-positive advanced NSCLC who have previously received crizotinib.
Adjuvant Treatment After Surgery
For certain adults with ALK-positive NSCLC who have undergone complete tumour removal and have a high risk of recurrence, alectinib may be used as postoperative adjuvant treatment.
Alectinib Dosage and Administration
The dosage of alectinib must be determined by the treating physician based on the patient's diagnosis, treatment setting, overall health, previous therapy and applicable prescribing information.
For the referenced adult treatment regimen, the recommended dose is 600 mg twice daily with food. With a 150 mg capsule formulation, this corresponds to four 150 mg capsules per dose, taken twice daily.
- Take alectinib exactly as prescribed.
- Take the capsules with food.
- Swallow the capsules whole with water.
- Do not change the dose without medical advice.
- Do not stop treatment without consulting the treating healthcare professional.
- Follow the prescribed treatment schedule consistently.
Missed Dose
If a dose is missed, follow the specific instructions provided with the medicine or contact the treating healthcare professional. Do not automatically take an extra dose to compensate for a missed dose.
Vomiting After a Dose
If vomiting occurs after taking alectinib, patients should follow the product-specific instructions or contact their healthcare team before taking another dose.
Alectinib Side Effects
Like other prescription anticancer medicines, alectinib can cause side effects. Their severity and frequency can vary from one patient to another.
Common Side Effects
- Constipation
- Muscle pain
- Swelling or oedema
- Anaemia
- Increased bilirubin levels
- Increased liver enzymes
- Fatigue
- Changes in muscle-related laboratory tests
Less Common or Clinically Important Side Effects
- Slow heart rate or bradycardia
- Liver toxicity
- Significant muscle pain or weakness
- Increased creatine phosphokinase levels
- Interstitial lung disease or pneumonitis
- Photosensitivity reactions
- Kidney-related laboratory abnormalities
Serious Side Effects
Serious reactions can include significant liver injury, interstitial lung disease or pneumonitis, clinically important bradycardia, severe muscle toxicity and serious hypersensitivity reactions.
When to Seek Medical Attention
Prompt medical assessment is important if a patient develops new or worsening breathing difficulty, persistent cough, severe muscle pain or weakness, dark urine, yellowing of the skin or eyes, fainting, severe dizziness, chest symptoms or signs of a serious allergic reaction.
Drug Interactions
Alectinib may interact with other medicines. Patients should provide their healthcare professional with a complete list of prescription medicines, over-the-counter products, vitamins and supplements.
Medicines Requiring Monitoring
- Strong CYP3A inducers
- Strong CYP3A inhibitors
- Medicines affected by P-glycoprotein or BCRP pathways
- Medicines that can reduce heart rate
- Medicines associated with muscle toxicity
- Medicines that may affect liver function
Food Considerations
Alectinib should be taken with food. Patients should discuss grapefruit, Seville oranges and other foods that may affect drug metabolism with their healthcare professional.
Supplement Considerations
Tell your doctor or pharmacist before using herbal medicines, St John's wort, high-dose supplements, traditional medicines or unregulated cancer-related products because these products may affect medicine metabolism or treatment safety.
Warnings and Precautions
Liver Considerations
Alectinib can cause changes in liver enzymes and bilirubin. Liver function testing may therefore be required during treatment.
Cardiovascular Considerations
Alectinib can cause bradycardia, meaning an abnormally slow heart rate. Patients with existing heart-rate problems or those taking medicines that affect heart rate should inform their healthcare professional.
Muscle Considerations
Muscle pain and increased creatine phosphokinase levels may occur. Severe or persistent muscle pain, weakness or dark urine should be reported promptly.
Lung Considerations
Interstitial lung disease or pneumonitis is an important potential safety concern. New or worsening cough, shortness of breath or other unexplained respiratory symptoms should be assessed promptly.
Photosensitivity
Alectinib may increase sensitivity to sunlight. Appropriate sun-protection measures may be recommended during treatment.
Special Monitoring Requirements
- Liver function and bilirubin
- Heart rate
- Muscle-related laboratory tests
- Kidney function when clinically appropriate
- Respiratory symptoms
- Other tests recommended by the treating oncology team
Pregnancy and Breastfeeding
Alectinib may pose a risk to an unborn baby. Patients who are pregnant, planning pregnancy or capable of becoming pregnant should discuss treatment and appropriate contraception with their healthcare professional.
Because treatment requirements can differ according to the individual clinical situation, contraception should be discussed with the treating physician. Breastfeeding should also be discussed with the healthcare professional, and patients should follow the specific prescribing recommendations for alectinib.
Special Populations
Elderly Patients
Older adults may require careful assessment of overall health, organ function, other medicines and treatment tolerance. Dosing should follow the applicable prescribing information and medical assessment.
Pediatric Patients
Alectinib is not automatically interchangeable between adult and pediatric treatment. Use in children should follow an approved indication and specialist medical guidance.
Renal Impairment
Patients with kidney impairment should inform their healthcare professional before treatment. Individual clinical assessment and appropriate monitoring may be required.
Hepatic Impairment
Liver function is particularly important during alectinib treatment. Patients with significant hepatic impairment may require specialized assessment and dose considerations.
Storage
Store alectinib according to the storage instructions provided on the specific product packaging and official product information.
- Keep the capsules in their original packaging.
- Store the medicine under the recommended environmental conditions.
- Keep out of reach of children.
- Do not use capsules that appear damaged or abnormal.
- Follow any specific temperature or storage instructions printed on the product label.
Frequently Asked Questions About Alectinib
What is alectinib used for?
Alectinib is a targeted anticancer medicine used for eligible patients with ALK-positive non-small cell lung cancer.
How does alectinib work?
Alectinib inhibits ALK tyrosine kinase activity and reduces abnormal signalling involved in the growth and survival of ALK-dependent cancer cells.
Is alectinib chemotherapy?
Alectinib is a targeted therapy rather than conventional cytotoxic chemotherapy. It specifically targets abnormal ALK signalling.
What is alectinib 150 mg?
Alectinib 150 mg is a capsule containing 150 mg of alectinib. Multiple capsules may be required to achieve the total dose prescribed by the physician.
What is the usual adult dose of alectinib?
The referenced adult treatment regimen is 600 mg twice daily with food. For 150 mg capsules, this equals four capsules per dose.
Should alectinib be taken with food?
Yes. Alectinib is recommended to be taken with food.
Can alectinib cure lung cancer?
Alectinib should not be considered a guaranteed cure. It is a targeted treatment used to manage ALK-positive NSCLC in appropriate patients.
What are the common side effects of alectinib?
Common effects may include constipation, muscle pain, swelling, anaemia, increased bilirubin and increased liver enzymes.
Can alectinib affect the liver?
Yes. Alectinib can affect liver enzymes and bilirubin, so liver-function monitoring may be required.
Can alectinib cause muscle pain?
Yes. Muscle pain and increases in creatine phosphokinase can occur. Severe or persistent symptoms should be reported to a healthcare professional.
Can alectinib affect heart rate?
Alectinib can cause bradycardia, which means a slower-than-normal heart rate. Medical monitoring may be required.
Can alectinib cause breathing problems?
Interstitial lung disease or pneumonitis can occur. New or worsening breathing problems should be medically assessed promptly.
Can alectinib be taken with grapefruit?
Patients should discuss grapefruit and Seville oranges with their healthcare professional because certain foods can affect medicine metabolism.
What happens if I miss an alectinib dose?
Do not automatically double the next dose. Follow the missed-dose instructions supplied with the medicine or contact your healthcare provider.
Is alectinib suitable for every lung cancer patient?
No. Alectinib is intended for specific patients whose cancer has an appropriate ALK alteration and who meet the relevant clinical criteria.
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides pharmaceutical information and specialty-medicine support for individuals and organizations seeking information about prescription and specialty medicines.
Our information resources are designed to help visitors understand medicines, therapeutic classes, treatment considerations, dosage information, safety precautions and common questions before discussing treatment with a qualified healthcare professional.
For specialty and oncology medicines such as alectinib, patients and organizations may require information regarding product strength, dosage form, prescription requirements, sourcing and applicable regulatory considerations.
RootAid Pharma can provide medicine-related information and supply assistance where legally and operationally applicable. Availability, prescription requirements, import regulations and delivery conditions can vary by country and should be confirmed before any medicine is supplied or used.
RootAid Pharma does not replace an oncologist, physician or pharmacist. Treatment decisions should always be made by an appropriately qualified healthcare professional.
Medical Disclaimer
This article is provided for general educational and informational purposes only. It is not a substitute for medical diagnosis, treatment planning, prescribing information or advice from a qualified physician, oncologist, pharmacist or other licensed healthcare professional.
Alectinib is a prescription anticancer medicine intended for specific patients with appropriate ALK-positive disease. Treatment selection, dosage, dose adjustments, monitoring, duration of therapy and management of side effects must be determined by the treating healthcare professional.
Medicine indications, approved uses, formulations, regulatory requirements and prescribing recommendations may differ between countries and may be updated over time. Patients should consult the official product information applicable to their country and follow the instructions of their healthcare professional.
Do not start, stop, increase or reduce alectinib without professional medical advice.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.